6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of 6-Thioguanine,
Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine
(CCNU) is effective in the treatment of recurrent or progressive anaplastic glioma or
glioblastoma multiforme in patients who have failed previous treatments. The safety of these
combination treatment will also be studied.
Objectives:
1.1 To determine the efficacy, as measured by 12 month progression-free survival, of
TEMOZOLOMIDE or CCNU with 6-THIOGUANINE followed by CAPECITABINE and CELECOXIB in the
treatment of patients with recurrent and/or progressive anaplastic gliomas or glioblastoma
multiforme.
1.2 To determine the long-term toxicity of TEMOZOLOMIDE or CCNU with 6-THIOGUANINE followed
by CAPECITABINE and CELECOXIB in recurrent anaplastic glioma or glioblastoma multiforme
patients treated in this manner.
1.3 To determine the clinical relevance of genetic subtyping tumors as a predictor of
response to this chemotherapy and long term survival